Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Hot Sheets Newsletter: 2019

Hot SHEET 2019

Made possible by charitable contributions from



 – Thank You!


Our monthly newsletter, the Hot SHEET, highlights the latest in treatment strategies as well as emerging treatments. The Hot SHEET is distributed free at chapter support group meetings, and is available in PDF on the Us TOO web site.

Subscribe to get the Hot SHEET (and other prostate cancer news and information) for free via email from Us TOO at www.ustoo.org/subscribe.

Hot SHEET Personal Subscriptions Now Available

If you are unable to attend chapter meetings to get the latest issue or prefer an original copy, we can deliver the newsletter right to your home or office. Download and print a subscription order form or order online.

  • Prostatectomy Beats Active Surveillance Long Term – or Does It?
  • Is No Surgery Feasible in Gleason 9 and 10 PCa?
  • Prostate Cancer Risk Lower in Long-Term Users of Lipid-Lowering Drugs
  • YouTube Videos Often Mislead on Prostate Cancer
  • Doc Moyad’s No Bogus Science: “Are Fish Oil Results a Little Fishy?!”
  • ADT May Be Less Beneficial for Gleason Score 9 to 10 Prostate Cancer
  • Doctor Chodak’s Bottom Line
  • Index of Articles Published in the 2018 Hot SHEET
  • RP Beats Surveillance, or Does It?
  • Overactive Bladder Linked to ADT for Prostate Cancer
  • New, Quicker Test to Assess Risk of PCa Metastasis
  • Short- vs. Intermediate-Term AS with RT & Zoledronic Acid
  • Doc Moyad’s Column: “Restaurants = Weight Gain?!”
  • PCa Risk Higher in Men with Inflammatory Bowel Disease
  • Hypofractionated RT & Pca
  • Combination Strategy IDs Pca
  • Gleason 6 PCa More Lethal in Black Men
  • Gold Nanoparticles Could Destroy Prostate Cancer
  • Survival – Black vs. White Men Receiving Docetaxel
  • Surrogate Marker for ADT
  • Doctor Chodak’s Bottom Line
  • Does Castrate in Prostate Cancer Need Revision?
  • Adjuvant Docetaxel No Help in High-Risk Prostate Cancer
  • AS Safe for Prostate Cancer Patients Under 60 Years Old
  • Time Interval to Biochemical Failure – Surrogate End Point?
  • PCa Death Risk Linked to Post EBRT Time to PSA Nadir
  • Doc Moyad’s Column: “Follow Breast Cancer for Lifestyle?!”
  • Fusion Biopsies in AS Predict Prostate Cancer Progression
  • QoL But Sexual Dysfunction Common After Prostate Cancer
  • Low Carb Diet & Walking May Ease Adverse Effects of ADT
  • Doctor Chodak’s Bottom Line
  • Adding MRI Does Not Boost Prostate Cancer Upgrading
  • Active Surveillance for Prostate Cancer Triples in U.S.
  • Abiraterone & Mortality Risk from Cardiovascular Disease
  • Darolutamide Results Promising in Nonmetastatic PCa
  • Phase III Trial of PROSTVAC Stopped Early Due to Futility
  • Stereotactic Body Radiotherapy Shows Long-Term Safety in PCa
  • Doc Moyad's No Bogus Science: "The Secret to Dog’s Long Life"
  • Radiological Agent Promising in Heavily-Treated mCRPC
  • Enzalutamide Plus ADT for Advanced Prostate Cancer
  • Minimal Benefit of Aspirin Post-Prostate Cancer Diagnosis
  • Doctor Chodak’s Bottom Line
  • Chemo for Early-Stage PCa? RTOG 0521 Says Maybe 
  • PET-Based Imaging Improves Metastases Detection in BCR 
  • Long-Term ADT Underused for Prostate Cancer 
  • Intervention Helps Prostate Cancer Patients with Choices 
  • Doc Moyad’s No Bogus Science: “Take/Want Nothing!?” 
  • Worry Postprostatectomy a Self-Fulfilling Prophecy 
  • Carbon-Ion Radiotherapy for PCa & Risk of Second Cancers 
  • Doctor Chodak’s Bottom Line
  • Validation of Androgen Receptor Splice Variant 7
  • Packing a PUNCH in Prostate Cancer Chemo, ADT & Surgery
  • Gleason 8 PCa Diagnosed at Biopsy Frequently Downgraded
  • ‘Trexit’ – a Clean Break from Trans-Rectal Prostate Biopsies
  • Clinical Utility of CTC Androgen Splice Variant-7 Status
  • High-Fat, Diet-Induced Prostate Cancer Development
  • Doc Moyad’s No Bogus Science: “Breakfast is Not Important?!”
  • Clinical Validation of IsoPSA™
  • Prostate Cancer Metastases at Diagnosis on the Rise
  • Active Surveillance in Black Men with Low-Risk Prostate Cancer
  • Sipuleucel-T Could Be More Widely Used for Advanced Prostate Cancer
  • ‘Fake News’ in Urology
  • Doctor Chodak’s Bottom Line
  • New Entry in ‘Burgeoning Field’ of Prostate Cancer Therapy
  • Misleading Advertising Claims by Proton Beam Therapy Centers 
  • More is Not Better in Treatment of Metastatic CRPC 
  • Apalutamide for Metastatic Castration-Sensitive Prostate Cancer 
  • Time to BCR After RP and Efficacy of Salvage Radiotherapy 
  • Evaluating the Safety of AS
  • Doc Moyad’s No Bogus Science: “Fruit Juice = Sugary Soda?!” 
  • MRI-Targeted vs. Systematic Biopsy 
  • Enzalutamide Joins Initial Treatment List for Metastatic PCa 
  • Satisfaction with Care Among Men with Localized PCa 
  • Doctor Chodak’s Bottom Line
  • Prostate Cancer Higher in 9/11 Responders – A Look at Why
  • ADT & Multiple Bone Properties
  • MRI Plus Systematic Sampling Ups First-Time Prostate Biopsy Hits
  • Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid & Initial ADT
  • Vitamin D Supplementation and Total Cancer Incidence and Mortality
  • Doc Moyad’s No Bogus Science: “PCa & Depression?!”
  • Socioenvironmental Adversity and Risk of PCa
  • Moderately Hypofractionated Proton Therapy for Localized PCa
  • ADT Use and Diagnosis of Dementia in Men with PCa
  • Body Fat Distribution Points to Prostate Cancer Aggressiveness
  • Doctor Chodak’s Bottom Line
  • FDA Approval for Darolutamide in Prostate Cancer
  • Elective Node Radiation Appears More Effective for Nodal Recurrence
  • DRE Is Still a Prognostic Tool
  • Validity of PROMIS Sexual Interest and Satisfaction Measures Post-RP
  • Toxicity of Prostate Only Versus Prostate & Pelvic Lymph Node IMRT
  • Doc Moyad’s No Bogus Science: “Boring B12 Testing & Vacuuming?!”
  • Obesity Tied to Worse Perioperative Outcomes of RP
  • Negative Predictive Value of Prostate Multi-Parametric MRI
  • Radiation Therapy May Have a Role in Oligometastatic Prostate Cancer
  • Men’s Testosterone Levels Determined by Where They Grow Up
  • Researchers Find Molecular Switch to Prolong Survival
  • Doctor Chodak’s Bottom Line
  • First Results for Nanosphere Focal Therapy in Prostate Cancer
  • Second Generation Antiandrogens Carry Heart Risks
  • Largest Real-World Study of Immunotherapy with PROVENGE
  • Phase III Study of ADT with Enzalutamide or Placebo
  • Salvage Radical Prostatectomy for Recurrent Prostate Cancer
  • Doc Moyad’s No Bogus Science: “Boring B12 Testing & Vacuuming?!”
  • Recent Global Patterns in PCa Incidence and Mortality Rates
  • Phase 1b Trial of Docetaxel, Prednisone and Pazopanib
  • Acute Toxicity from IMRT vs. Stereotactic Body RT
  • New Prostate Cancer Blood Test Could Reduce Biopsies
  • Dr. Chodak’s Bottom Line
  • Cleveland Diagnostics’ PCa Test Gains Breakthrough Status
  • Skipping Radiotherapy After Surgery for Prostate Cancer
  • Durable Pain Control After Single RT Dose to Bone Metastases
  • "Landmark" Trial in Prostate Cancer with Mutations
  • New Blood Test is Highly Accurate and Avoids Invasive Biopsies
  • Doc Moyad's No Bogus Science Column: "Thank you Dr. Chodak for Being You"
  • RP vs. RT for High-Risk PCa with Low PSA Levels
  • "Passing Through" – In Memory of Gerald Chodak, MD
  • Men Just Want to Have Fun in Prostate Cancer Trial
  • Scientists Identify New Family of Drugs to Combat Prostate Cancer
  • 68Ga-PSMA-11 PET Detects Residual Prostate Cancer After RP
  • Positive Phase 3 HERO Study of Oral Relugolix in Advanced PCa
  • From Canada: Night Shift Work and Risk of Prostate Cancer
  • Grade Group Prediction from RP Final Pathology on Positive MRI
  • Doc Moyad's No Bogus Science Column: "Lifestyle Change or ISCHEMIA?"
  • Gold Nanoparticles are a Safe and Effective Treatment for PCa
  • AS for Intermediate-Risk PCa? Yes, But for Whom?
  • Oncology Patients Increasingly Ask About Diet – What to Say?
  • MRI in Early Detection of Prostate Cancer
  • Guest Column: Living w. Prostate Cancer, Talking About Sex


More Resources